Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of IV and Intranasal Oxytocin in Healthy Subjects
NCT05672667Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2023
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxytocin nasal spray in chronic migraine, sponsored by Wake Forest University Health Sciences. Primary endpoints: Plasma Oxytocin Concentration After IV Infusion and Plasma Oxytocin Concentration After Intranasal Administration. Started Feb 2023; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT05672667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672667.